MBS2320 might have escaped your
attention. In 2019 there had been a poster at the EULAR Annual
Meeting and this year there should have been an oral presentation.
MBS2320
is a
novel selective modulator of immune metabolism. I haven't found much
elucidation of what the compound selectively modulates [1]. The study
I'll talk about here says: „MBS2320
is a
selective modulator of immune metabolism displaying distinctive dual
pharmacology: strong anti-inflammatory activity as well as a broader
spectrum of osteoprotection
than TNFα
inhibition
in preclinical models.“ [2] It is a reference to the poster
presentation a year ago, both times L. Patel has been the first
author. Adis Insight has as most recent event: „13
Aug 2019 /
Modern Biosciences completes a phase IIa trial in Rheumatoid
arthritis (Adjunctive treatment) in Moldova, Romania and Georgia
(NCT03139136) (EudraCT2016-004038-24)“ [3]. So, we're really up to
date.
L.
Patel and colleagues presented the following study [2]: „OP0234
MBS2320,
A NOVEL SELECTIVE MODULATOR OF IMMUNE METABOLISM, IN PATIENTS WITH
SEVERE RHEUMATOID ARTHRITIS: SAFETY, TOLERABILITY AND EFFICACY
RESULTS OF A PHASE 2 STUDY.“ It's a phase 2 study with dose
escalation of MBS2320 after 4 weeks from 80mg to 120mg in patients,
who tolerated 80 mg. The study lasted for 12 weeks. Of the 121
randomized patients only 96 completed the study; that's a loss of
about 21%. The results show an increase of response rates in the
verum group, but aren't comparable to other studies. Authors'
conclusions: „MBS2320
was generally well tolerated for up to 12 weeks in this RA
study population. Nausea was the most common TEAE, was generally mild
in severity and resolved without treatment. In this population of
patients with hardtotreat, severe, active, erosive disease MBS2320
showed evidence of a clinical benefit
on both ACR20 responses and DAS28-CRP.“
I'm
always happy if new novel mechanisms of action in anti-rheumatic
drugs make it into phase 2 and 3 studies. Will there be a drug in
coming years? Hard to tell as we lack precise information on the mode
of action. I'd wish to have a comparator like a biologic agent or
another small molecule like a JAK-inhibitor. I guess that there will
be. Hopefully we don't have to wait too long.
Links and References:
[2] L. Patel1, L.
Skillern1, M. Foster1, A. Gray1, R. Leff2, S. Williams1. 1Istesso
Ltd,
London, United Kingdom;
2Richard Leff LLC, Philadelphia, United States of America. OP0234
MBS2320, A NOVEL SELECTIVE MODULATOR OF IMMUNE METABOLISM, IN
PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS: SAFETY, TOLERABILITY AND
EFFICACY RESULTS OF A PHASE 2 STUDY. DOI:
10.1136/annrheumdis-2020-eular.3804.
.
No comments:
Post a Comment